Hepatitis Testing Market Size, Share, Trends, Growth Outlook

Hepatitis Testing Market is estimated to increase at a Compounded Annual Growth Rate of 4.3% CAGR over the forecast period from 2024 to 2030

The Hepatitis Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Disease (Hepatitis B (HBV), Hepatitis C (HCV), Others), By Technology (Enzyme-linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Others), By End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Others).

An Introduction to Hepatitis Testing Market in 2024

Hepatitis testing involves the detection and diagnosis of viral hepatitis infections, including hepatitis A, B, C, D, and E, through serological tests that detect viral antigens or antibodies in blood samples. In 2024, hepatitis testing remains a critical component of public health efforts to identify and manage hepatitis infections, prevent transmission, and reduce the burden of liver disease worldwide. Hepatitis testing may involve screening individuals at risk for hepatitis exposure, such as healthcare workers, injection drug users, or individuals with high-risk sexual behaviors, as well as diagnosing patients with symptoms suggestive of acute or chronic hepatitis infection. Serological tests for hepatitis typically include enzyme immunoassays (EIAs), chemiluminescent immunoassays (CLIAs), and polymerase chain reaction (PCR) tests, which detect viral antigens or antibodies and viral nucleic acids, respectively. Additionally, point-of-care tests (POCTs) are available for rapid hepatitis screening in community settings or resource-limited environments. Early detection of hepatitis infections allows for timely medical intervention, including antiviral therapy, vaccination, or counseling on risk reduction behaviors. Moreover, hepatitis testing plays a crucial role in surveillance efforts to monitor disease prevalence, track transmission patterns, and inform public health strategies for hepatitis prevention and control. With the availability of highly sensitive and specific diagnostic tests, hepatitis testing continues to be a cornerstone of efforts to combat viral hepatitis and improve liver health on a global scale.

Market Trend: Increased Focus on Early Detection and Screening Initiatives

A prominent trend in the hepatitis testing market is the increased focus on early detection and screening initiatives. With hepatitis infections posing significant public health challenges globally, there is growing recognition of the importance of early diagnosis and intervention to prevent disease transmission and progression. Healthcare organizations, government agencies, and non-profit organizations are implementing screening programs and awareness campaigns to promote hepatitis testing among at-risk populations, including injection drug users, individuals with high-risk sexual behaviors, and immigrants from endemic regions. This trend reflects the shift towards proactive disease management strategies and the demand for comprehensive hepatitis testing solutions that offer accurate, rapid, and cost-effective diagnostic options, driving market growth and adoption of hepatitis testing technologies.

Market Driver: Rising Incidence of Hepatitis Infections

A primary driver fueling the growth of the hepatitis testing market is the rising incidence of hepatitis infections worldwide. Hepatitis viruses, including hepatitis B virus (HBV) and hepatitis C virus (HCV), are major causes of liver disease, cirrhosis, and hepatocellular carcinoma, contributing to significant morbidity and mortality globally. Factors such as unsafe injection practices, blood transfusions, and unprotected sexual activity contribute to the spread of hepatitis infections, while the lack of effective vaccines and treatment options underscores the importance of early detection and management. As healthcare systems grapple with the burden of hepatitis-related diseases, there is a growing need for reliable and accessible hepatitis testing solutions to facilitate timely diagnosis, treatment initiation, and disease surveillance, supporting market expansion and investment in hepatitis testing technologies.

Market Opportunity: Development of Point-of-Care Hepatitis Testing Devices

An enticing opportunity within the hepatitis testing market lies in the development of point-of-care (POC) hepatitis testing devices. POC testing offers the advantage of delivering rapid diagnostic results at the point of patient care, enabling immediate clinical decision-making and treatment initiation. Given the challenges associated with traditional laboratory-based testing methods, such as long turnaround times and limited access in resource-limited settings, there is a growing demand for POC hepatitis testing devices that offer simplicity, portability, and accuracy. By investing in the development of POC testing platforms for hepatitis B and hepatitis C, manufacturers can address unmet needs in healthcare delivery, improve patient outcomes, and expand market reach to underserved populations, presenting opportunities for innovation and growth in the competitive hepatitis testing market.

Hepatitis Testing Market Share Analysis: Hepatitis C (HCV) Testing Market is the fastest growing segment over the forecast period to 2030

In the Hepatitis Testing Market, the segment experiencing the most rapid growth is the Hepatitis C (HCV) Testing Market. This growth is driven by several key factors. Firstly, Hepatitis C infection is a significant global health burden, with millions of people affected worldwide. The high prevalence of Hepatitis C, coupled with the availability of effective antiviral treatments, has led to increased awareness and screening efforts to identify individuals infected with the virus. As a result, there is a growing demand for Hepatitis C testing services in healthcare settings, including hospitals, diagnostic laboratories, and blood banks. Secondly, advancements in diagnostic technologies have improved the accuracy, sensitivity, and accessibility of Hepatitis C testing methods. Polymerase Chain Reaction (PCR) and Isothermal Nucleic Acid Amplification Technology (INAAT) are highly sensitive molecular techniques that allow for the detection of HCV RNA in blood samples, enabling early diagnosis and treatment monitoring. Rapid Diagnostic Tests (RDTs) offer a convenient point-of-care testing option for screening individuals at risk of Hepatitis C infection, providing rapid results without the need for specialized laboratory equipment. Thirdly, initiatives aimed at eliminating Hepatitis C as a public health threat, such as the World Health Organization's Global Hepatitis Strategy and national Hepatitis C elimination programs, drive the expansion of Hepatitis C testing services and screening campaigns. These efforts focus on identifying undiagnosed cases, linking infected individuals to care, and providing access to antiviral therapy to achieve the goal of reducing Hepatitis C-related morbidity and mortality. Moreover, the integration of Hepatitis C testing into routine healthcare services, such as HIV testing and antenatal care, contributes to increased testing coverage and facilitates early detection of Hepatitis C infection among at-risk populations. As a result, the Hepatitis C Testing Market emerges as the fastest growing segment in the Hepatitis Testing Market, driven by the pressing need to address the global Hepatitis C epidemic and achieve the targets outlined in Hepatitis C elimination initiatives.

Hepatitis Testing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc, Danaher Corp, DiaSorin S.P.A., Epitope Diagnostics Inc, F. Hoffmann-La Roche Ltd, Fujirebio US Inc, geneOmbio Technologies Pvt. Ltd, GenMark Diagnostics Inc, Grifols S.A., MedMira Inc, Meril Life Sciences Pvt. Ltd, Molbio Diagnostics Pvt. Ltd, OraSure Technologies Inc, Ortho Clinical Diagnostics, QIAGEN, Siemens Healthineers AG, Trivitron Healthcare Pvt. Ltd, Vela Diagnostics Pte. Ltd

Hepatitis Testing Market Segmentation

By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Hepatitis Testing Market Companies

Abbott Laboratories
bioMérieux SA
Bio-Rad Laboratories Inc
Danaher Corp
DiaSorin S.P.A.
Epitope Diagnostics Inc
F. Hoffmann-La Roche Ltd
Fujirebio US Inc
geneOmbio Technologies Pvt. Ltd
GenMark Diagnostics Inc
Grifols S.A.
MedMira Inc
Meril Life Sciences Pvt. Ltd
Molbio Diagnostics Pvt. Ltd
OraSure Technologies Inc
Ortho Clinical Diagnostics
QIAGEN
Siemens Healthineers AG
Trivitron Healthcare Pvt. Ltd
Vela Diagnostics Pte. Ltd

Reasons to Buy the Hepatitis Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Hepatitis Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Hepatitis Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Hepatitis Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Hepatitis Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Hepatitis Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Hepatitis Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Hepatitis Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Hepatitis Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Hepatitis Testing Industry
4.2 Key Market Trends in Hepatitis Testing Industry
4.3 Potential Opportunities in Hepatitis Testing Industry
4.4 Key Challenges in Hepatitis Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Hepatitis Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Hepatitis Testing Market Outlook by Segments
7.1 Hepatitis Testing Market Outlook by Segments, $ Million, 2021- 2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others

8 North America Hepatitis Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Hepatitis Testing Markets in 2024
8.2 North America Hepatitis Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Hepatitis Testing Market size Outlook by Segments, 2021-2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others

9 Europe Hepatitis Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Hepatitis Testing Markets in 2024
9.2 Europe Hepatitis Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Hepatitis Testing Market Size Outlook by Segments, 2021-2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others

10 Asia Pacific Hepatitis Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Hepatitis Testing Markets in 2024
10.2 Asia Pacific Hepatitis Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Hepatitis Testing Market size Outlook by Segments, 2021-2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others

11 South America Hepatitis Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Hepatitis Testing Markets in 2024
11.2 South America Hepatitis Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Hepatitis Testing Market size Outlook by Segments, 2021-2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others
12 Middle East and Africa Hepatitis Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Hepatitis Testing Markets in 2024
12.2 Middle East and Africa Hepatitis Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Hepatitis Testing Market size Outlook by Segments, 2021-2030
By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
bioMérieux SA
Bio-Rad Laboratories Inc
Danaher Corp
DiaSorin S.P.A.
Epitope Diagnostics Inc
F. Hoffmann-La Roche Ltd
Fujirebio US Inc
geneOmbio Technologies Pvt. Ltd
GenMark Diagnostics Inc
Grifols S.A.
MedMira Inc
Meril Life Sciences Pvt. Ltd
Molbio Diagnostics Pvt. Ltd
OraSure Technologies Inc
Ortho Clinical Diagnostics
QIAGEN
Siemens Healthineers AG
Trivitron Healthcare Pvt. Ltd
Vela Diagnostics Pte. Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Disease
Hepatitis B (HBV)
Hepatitis C (HCV)
Others
By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Rapid Diagnostic Tests (RDT)
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End-User
Hospitals
Diagnostic Laboratories
Blood Banks
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)